Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03095274
Title Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Tumores Neuroendocrinos
Indications

islet cell tumor

neuroendocrine tumor

pulmonary neuroendocrine tumor

gastrointestinal neuroendocrine tumor

Therapies

Durvalumab

Tremelimumab

Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.